The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

ImmunoGen Inc

Nasdaq: IMGN
Last

(U.S.) $7.28

Today's change+0.19 +2.68%
Updated February 12 4:15 PM EST. Delayed by at least 15 minutes.
 

ImmunoGen Inc

Nasdaq: IMGN
Last

(U.S.) $7.28

Today's change+0.19 +2.68%
Updated February 12 4:15 PM EST. Delayed by at least 15 minutes.

ImmunoGen Inc up sharply

ImmunoGen Inc closed up sharply Friday, rallying (U.S.)$0.19 or 2.68% to (U.S.)$7.28. Over the last five days, shares have lost 4.71% and are down 46.35% for the last year to date. This security has outperformed the S&P 500 by 11.96% during the last year.

Key company metrics

  • Open(U.S.) $7.24
  • Previous close(U.S.) $7.09
  • High(U.S.) $7.35
  • Low(U.S.) $6.77
  • Bid / Ask-- / --
  • YTD % change-46.35%
  • Volume1,030,383
  • Average volume (10-day)1,364,841
  • Average volume (1-month)1,139,357
  • Average volume (3-month)1,047,745
  • 52-week range(U.S.) $6.77 to (U.S.) $19.43
  • Beta1.93
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.37
Updated February 12 4:15 PM EST. Delayed by at least 15 minutes.
S&P TSX2.43%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue18151311
Total other revenue--------
Total revenue18151311
Gross profit--------
Total cost of revenue--------
Total operating expense46433833
Selling / general / administrative8877
Research & development38353026
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-28-29-25-21
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-33-34-30-22
Income after tax-33-34-30-22
Income tax, total--------
Net income-33-34-30-22
Total adjustments to net income--------
Net income before extra. items-33-34-30-22
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-33-34-30-22
Inc. avail. to common incl. extra. items-33-34-30-22
Diluted net income-33-34-30-22
Dilution adjustment--------
Diluted weighted average shares87878686
Diluted EPS excluding extraordinary itemsvalue per share-0.38-0.39-0.35-0.25
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.38-0.39-0.35-0.25